Atyr Pharma INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 2,471,418 shares, representing 2.5% of ATYR PHARMA INC's common stock as of June 30, 2026.

Federated Hermes, Inc. and associated entities have filed an amended Schedule 13G, reporting beneficial ownership of 8,509,678 shares, representing 8.68% of aTyr Pharma Inc.'s common stock.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting a 6.1% beneficial ownership stake in aTyr Pharma Inc.

Federated Hermes, Inc. and its affiliated entities reported a beneficial ownership of 10.76% in aTYR PHARMA INC common stock as of September 30, 2025.

The Vanguard Group has reported a passive beneficial ownership of 5.23% in aTyr Pharma Inc., holding 4,655,048 shares of common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.5% in aTYR Pharma Inc.'s common stock as of June 30, 2025.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have disclosed a combined passive beneficial ownership of 3.2% in aTyr Pharma Inc., totaling 2,845,354 shares as of March 31, 2025.

Federated Hermes, Inc., along with the Donahue family and related trusts, has disclosed a beneficial ownership of 17.47% of ATYR Pharma, Inc.'s common stock as of December 31, 2024.